A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa, PROCRIT) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa, PROCRIT) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms LTTO
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 11 Feb 2013 Actual initiation date changed from May 2005 to Aug 2005 as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Additional lead trial investigator (Tracy McGowan) identified as reported by ClinicalTrials.gov.
    • 07 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top